286 related articles for article (PubMed ID: 22717078)
21. Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.
Mossaheb N; Spindelegger C; Asenbaum S; Fischer P; Barnas C
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):502-5. PubMed ID: 20218805
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotic polypharmacy in schizophrenia: benefits and risks.
Barnes TR; Paton C
CNS Drugs; 2011 May; 25(5):383-99. PubMed ID: 21476610
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Said MA; Hatim A; Habil MH; Zafidah W; Haslina MY; Badiah Y; Ramli MA; Ananjit S; Sapini Y; Shah M; Mahmud B; Bulgiba A; Hairi NN
Prev Med; 2013; 57 Suppl():S50-3. PubMed ID: 23337566
[TBL] [Abstract][Full Text] [Related]
24. The use of aripiprazole in early onset schizophrenia: safety and efficacy.
Normala I; Hamidin A
Med J Malaysia; 2009 Sep; 64(3):240-1. PubMed ID: 20527278
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
[TBL] [Abstract][Full Text] [Related]
26. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
27. Repeated creatine kinase elevation under treatment with quetiapine, clozapine, and aripiprazole in an adolescent.
Bachmann CJ; Nicksch B; de Lange D; Theisen FM; Remschmidt H
J Clin Psychopharmacol; 2007 Dec; 27(6):710-1. PubMed ID: 18004144
[No Abstract] [Full Text] [Related]
28. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
Lähteenvuo M; Tiihonen J
Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
[TBL] [Abstract][Full Text] [Related]
29. A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.
Honer WG; Procyshyn RM; Chen EY; MacEwan GW; Barr AM
J Psychiatry Neurosci; 2009 Nov; 34(6):433-42. PubMed ID: 19949719
[TBL] [Abstract][Full Text] [Related]
30. Aripiprazole: pharmacology, efficacy, safety and tolerability.
Kinghorn WA; McEvoy JP
Expert Rev Neurother; 2005 May; 5(3):297-307. PubMed ID: 15938662
[TBL] [Abstract][Full Text] [Related]
31. Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents.
Prescrire Int; 2009 Dec; 18(104):251. PubMed ID: 20025091
[No Abstract] [Full Text] [Related]
32. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
33. Interventions to reduce antipsychotic polypharmacy: a systematic review.
Tani H; Uchida H; Suzuki T; Fujii Y; Mimura M
Schizophr Res; 2013 Jan; 143(1):215-20. PubMed ID: 23158205
[TBL] [Abstract][Full Text] [Related]
34. Variation in long-term antipsychotic polypharmacy and high-dose prescribing across physicians and hospitals.
Latimer EA; Naidu A; Moodie EE; Clark RE; Malla AK; Tamblyn R; Wynant W
Psychiatr Serv; 2014 Oct; 65(10):1210-7. PubMed ID: 24981557
[TBL] [Abstract][Full Text] [Related]
35. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.
Ijaz S; Bolea B; Davies S; Savović J; Richards A; Sullivan S; Moran P
BMC Psychiatry; 2018 Sep; 18(1):275. PubMed ID: 30176844
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
37. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
[TBL] [Abstract][Full Text] [Related]
38. Trial of aripiprazole in the treatment of first-episode schizophrenia.
Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
[TBL] [Abstract][Full Text] [Related]
39. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.
Park SC; Lee MS; Kang SG; Lee SH
J Korean Med Sci; 2014 May; 29(5):719-28. PubMed ID: 24851031
[TBL] [Abstract][Full Text] [Related]
40. Use of Aripiprazole in treatment resistant schizophrenia.
Hughes D; Morcos M
J Psychopharmacol; 2008 Nov; 22(8):927-8. PubMed ID: 18308805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
